List view / Grid view
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
Here, Dave Elder discusses the ever increasing importance of child-friendly medications and the specific challenges associated with their development.
Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) gives her take on the industry response to the pandemic; highlighting the benefits of focused effort and what can be achieved through unified collaboration.
Infusion is the most used technology in hospitals. Given its widespread application, often in critical situations and by many users, infusion errors are frequently made, with some having severe effects. Here, Emmelyn Graham, Flow Measurement Engineer at TÜV SÜD National Engineering Laboratory, and Elsa Batista, Head of Volume and Flow…
It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature-300x278.jpg)
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature.jpg)
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…
David Vincent, Process Development Lead at eXmoor Pharma, details some of the critical steps that form the manufacturing strategy for providers of cell and gene therapies.
Features in this in-depth focus highlight some of the important developments in the cell and gene therapy market, as well as the key manufacturing strategies to consider when taking them from concept to commercialisation.
In this in-depth focus, learn how to overcome interfering factors when using LAL for endotoxin testing and discover how the implementation of a new scrubs system benefited an aseptic production facility.
Featured in this in-depth focus: why improving dosing accuracy with infusion pumps requires users to have a better understanding of the equipment and how nanomedicines could be instrumental in improving skin and nail diseases.
Download this in-depth focus to discover why shifting away from traditional bioproduction and drug delivery systems could allow antibodies to reach their full potential and how Raman spectroscopy can give useful insights into your processes.
Here, colleagues from University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) share the beneficial impact of reduced cleanroom environmental contamination following an upgrade to their facilities and procedures.
The Bacterial Endotoxin Test, using LAL methodology, is a key in-process and final product release test for sterile pharmaceuticals and medical devices. One of the challenges with LAL methodology is overcoming interfering substances as demonstrated by inhibition or enhancement of an endotoxin challenge. Here, Bio Products Laboratory’s Dr Tim Sandle…
In our latest issue, features explore the use of nano formulations to improve skin and nail drug delivery, how to take cell and gene therapies from concept to commercialisation and what strategies you can use to overcome interfering factors in LAL bacterial endotoxin testing. Also in this journal, find out…
